Research programme: selective aryl hydrocarbon receptor modulators - Actavalon
Alternative Names: Aryl hydrocarbon receptor modulators; SAhRMLatest Information Update: 28 Sep 2022
At a glance
- Originator Actavalon
- Class Antineoplastics; Small molecules
- Mechanism of Action Aryl hydrocarbon receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA
- 21 Aug 2018 Preclinical trials in Triple-negative-breast-cancer in USA (unspecified route) (Actavalon pipeline, August 2018)